IMC-002 (Suzhou Immunofoco)

N/A

Report date: 2025/12/18 17:42:31

Base Information

Drug NameIMC-002 (Suzhou Immunofoco)
Drug Alias Nameautologous claudin 18.2 specific CAR T- cell therapy (Suzhou Immunofoco Biotechnology)Claudin 18.2 CAR-T (Suzhou Immunofoco Biotechnology)IMC-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Immunofoco Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Immunofoco Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A